IRD Rose 8.2% After Opus Genetics Inducement Grants
Opus Genetics (Nasdaq: IRD) rose 8.2% on Aug 19, 2026 after the company disclosed inducement equity grants tied to three new employee hires.
What Opus Genetics announced
Opus Genetics said its board compensation committee approved equity awards under the company’s 2021 Inducement Plan, as amended. The grants were described as a “material inducement” to employment for three non-executive employees who were not previously employees or directors. The company noted the awards were approved in line with Nasdaq Listing Rule 5635(c)(4), a rule that covers certain equity grants made as a hiring incentive. In plain English: this was a hiring-related stock award disclosure, not a product update.
What it means for Opus Genetics
Inducement grants are typically used to recruit and retain employees, especially in competitive biotech talent markets. By using its inducement plan and citing the Nasdaq rule, Opus is signaling the awards were structured specifically for new hires and handled through the required governance process. While the announcement doesn’t change the company’s clinical-stage status or provide new data, it could indicate ongoing build-out of the team needed to advance gene therapy programs. It also highlights that the company is using equity compensation as part of its hiring toolkit.
How the stock reacted
Shares moved higher quickly and finished the session up sharply.
| Window | Move |
|---|---|
| 5 min | +2.1% |
| 10 min | +1.9% |
| 30 min | +2.3% |
| 1 hour | +3.7% |
| end of day | +8.2% |
On a market-adjusted basis, IRD outperformed the S&P 500 by +8.3% the same day.